Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report

AbstractRationale:While checkpoint inhibitors have revolutionized the treatment of melanoma, it is not known whether switching from one monoclonal antibody drug to another one would be justified in the case of a treatment failure. Herein, we report a case illustrating a durable response to pembroliz